CNS (Central Nervous System) and Chronic Drug Trials: New Cardiac Safety Requirements, Upcoming Webinar Hosted by Xtalks
TORONTO, Ontario, Canada, April 28, 2023 /PRNewswire-PRWeb/ -- Drugs that are chronically administered, such as those for CNS disease states, are under increased scrutiny for potential effects on cardiac safety endpoints, and for good reason. Whereas a small change in blood pressure may be inconsequential for drugs administered over a short timeframe, the story is very different for drugs that are likely to be taken for years or decades. Prolonged changes in blood pressure or QT interval are associated with a variety of patient health risks and prescribers need to carefully weigh the risks and benefits. Regulatory agencies understand this challenge and have drafted recent guidance to better detect even small changes in cardiac safety, ensuring that a drug's risk profile is well-established during development, with increased attention given to chronically administered drugs.
- In this free webinar, learn about potential upcoming changes for cardiac safety requirements for CNS and chronically administered drugs.
- TORONTO, Ontario, Canada, April 28, 2023 /PRNewswire-PRWeb/ -- Drugs that are chronically administered, such as those for CNS disease states, are under increased scrutiny for potential effects on cardiac safety endpoints, and for good reason.
- For long-term CNS drugs, blood pressure evaluation has become a critical consideration to establish the potential risk for stroke or other cardiovascular diseases.
- Join featured experts from Clario as they discuss the cardiac safety requirements (BP & ECG) for CNS and chronically administered drugs.